

Overview

Pathogenesis

Clinical features

Red flags

- Atlanto axial subluxation
- Pericarditis
- Monoarticular flare
- Eye involvement

Other manifestations

Dg

- History
- PE
- Labs
- Imagings
- Synovial fluid analysis

Differential Dg

Overview

Chronic systemic inflammatory disease
 Wide spectrum manifestations $\begin{cases} \text{articular} \\ \text{extra-articular} \end{cases}$
 Joint destruction $\rightarrow$ deformities $\rightarrow$ disability
 Mortality Morbidity
 Early Dg
 Early DMARDs $\rightarrow$ progression

Pathogenesis

Genetic predisposition: HLA DR1 and 4
 Environmental triggers: smoking $\rightarrow$ $\uparrow$ citrullination
 Auto immune synovitis $\rightarrow$ hypertrophy $\rightarrow$ destruction of bone cartilage $\rightarrow$ progressive joint damage $\rightarrow$ disability
 $\uparrow$
 dysregulated inflammatory process
 $\downarrow$
 extra articular tissues

Cells T and B

Cytokines TNF α and IL6



Dysregulated inflammation
 Dysequilibrium of cytokines

Clinical features

- Dg
- Activity
- Severity
- Extra articular manifestations

Sex ratio: 3:1 ♀ > ♂

♀: increase from mid 20s To peak between 45-75 y
♂ rare before 30 y



Red flags 🧐

Atlanto-axial subluxation	Atlanto axial joint involvement may be asymptomatic <u>suspect subluxation:</u> Pain around the occiput Radiating arm pain Numbness, weakness of the limbs Vertigo on neck mts	Presurgical evaluation: lat. views of cervical spine in flexion and extension
Pleuritis	Chest pain worsened by lying flat Accompanied by pleural rub	Echocardiogram Steroids Rule out infective causes (TB) - aspiration
Monoarticular flare	Single joint worsening <u>septic arthritis</u> or a flare ↳ predisposed ↳ immunosuppressed (RA mtl)	Aspiration → rule out septic arthritis - Prudent not initiation for septic arthritis until it is ruled out
Eye, scleritis	Sudden onset of eye pain Risk of perforation: Scleromalacia perforans	Look for it

Other manifestations

- Neurological → entrapment neuropathies Carpal Tunnel sd
- Ocular → scleritis episcleritis xerophthalmia
- Pulmonary → pleural effusion interstitial LD bronchiolitis obliterans
- Cardiac → pericarditis Coronary vasculitis (rare)
- Hematological → Anemia Thrombocytosis Felty's sd
- Cutaneous → skin nodules Cutaneous vasculitis leg ulcers
- Other → Xerostomia Osteoporosis

Diagnosis

History

Time: onset and progression with time

Distribution:

- progressive pattern of joint involvement
- stiffness
- ↑ pain after period of inactivity
- joint swelling
- ⇒ inflammation

Family hx of autoimmune disease → suspicion

PE

Distribution Chronicity Inflammatory Extra articular

Distribution: symmetrical involvement of hands (MCP, PIP, wrists) with relative sparing of axial skeleton.

Chronicity

Inflammatory: swelling tenderness restriction of mvs of the joint

Extra articular

- Support → rheumatoid nodules
- refuge → psoriatic patches

Labs

Blood:

- ↑ ESR, ↑ CRP
 - ↑ platelets
 - ↑ ferritin
 - Anaemia of chronic disease
 - if ↑ Leucocytes → infection
- } Acute phase response may not be present in early

Antibodies:

RF

Anti CCP → more specific

Synovial fluid analysis

Nonocuticular presentation

to rule out: infectious crystal etiology

- ↑ protein
- ↑ leukocytes
- φ crystals
- φ organisms Gram stain/culture.

Imaging

Plain x Rays

Periarticular erosions within first 3 years
Juxta articular osteopenia
Joint space narrowing } earlier less specific

MRI: Soft tissue changes

- synovitis
- bone edema
- early erosive changes

4/5 of small joints

synovitis
joint erosions

High resolution CT

interstitial lung disease

Differential

Joint involvement pattern $\rightarrow$ distinguishable RA

Atypical presentation $\rightarrow$ challenging Ag

psoriatic arth. - nail pitting or skin lesions

Crystal " $\rightarrow$ aspiration

Other connective tissue diseases - SLE...

Hep B and C } in mind
HIV

2010 ACR/EULAR classification criteria of RA

Patients with:

I) ≥ 1 joint synovitis clinically

II) no better explanation by another disease (after exclusion)

A	B	C	D
Articular /5	anti Body /3	CRP/ESR /1	Duration /1

A. Articular Joints involvement /5

Large	1	$\rightarrow$ 0
	2-10	$\rightarrow$ 1
Small	1-3	$\rightarrow$ 2
	4-10	$\rightarrow$ 3
> 10 (with ≥ 1 small)		$\rightarrow$ 5

B. anti Bodies : Serology /3

⊖ RF and anti CCP	$\rightarrow$ 0
low " or "	$\rightarrow$ 2
high " or "	$\rightarrow$ 3

C. CRP/ESR Acute phase reactant


normal	$\rightarrow$ 0
abnormal	$\rightarrow$ 1

D. Duration

< 6 weeks	$\rightarrow$ 0
$\geq$ 6 weeks	$\rightarrow$ 1





RA

Systemic condition with predominant manifestations on periph. joints
Major cause of disability.



Pathogenesis

1) Cellular pathology



2) Genetic factors

Identical twins concordance rate ~ 30%

- Genetic contribution
 - Non inherited factors are important too
- } Poly factorial

4) PTP N22 polymorphism

Protein Tyrosine Phosphatase N22 receptor. lymphocyte specific
 ↳ Suppressing activation of T cells

1858T allele → ↑ susceptibility to RA
 Diabetes I
 Auto immune

5) Antibodies

RF: Ab anti Fc portion of IgG

IgM +++

IgA

IgG

Anti CCP

Citrullination - loss of amino group from Tyr residues
 occurs in healthy people
 at sites of inflammation

RA: dupl of Ab against citrullinated auto-antigen collagen type II
 Vimentin

6) Cytokines

Mφ
 Fibroblast like cells } cytokines
 ↳ Chemokines

TNFα
 IL 1
 IL 6
 IL 8
 GM-CSF

→ inflammatory cells → migration activation

Cytokines
 IL 7, 12, 15, 11

→ T cells costimulation →

↳ Th 17 → ↑ IL 17 ++ ↑

IFNγ
 IL 2
 IL 4

← sparsely expressed ↓

Abundant expression of anti-inflammatory cytokines
 up-regulated
 insufficient to suppress synovitis

IL 10
 IL 13
 TGF β

and
 IL 1 ra
 TNF soluble receptors

Concept of cytokine disequilibrium

TNFα Dominant position in the apex of pro-inflam cytokines network

(block { TNFα → no IL 1 and others
 IL 1 → still be TNFα





TNFα Pleiotropic

↑ → ↑ synovial proliferation
 ↑ → prostaglandins production
 ↑ → Metalloproteinase production


antiTNF ameliorate symptoms
 prevent joint destruction

Twins [identical → 30% → genetic + environmental } → polygenetic and not a single gene.
 [non identical → 5%]

3) HLA polymorphism



HLA II on CPA₂



- : modify auto Ag
- : DC : CPA
- : T cell
- : B. cells → plasma → Y Ab
- Immune complexes
- Mast cells → vasoactive mediators
- Ag Ab Complement cytokines chem

Cells	Cells	Humoral?
DC	Immune	Enzymes
T, B, Plasma	DC Mφ	• PADI
Mastocytes	T, B, Plasma	• Proteolytic
FLS	Mast	
Macrophages	Neutro	
	Neutro	
	FLS	
	Osteoclasts	
		Immune
		Ag modified
		Ab
		Immune complexes
		Vasoactive products
		Complement products
		Cyto. chemokines

Def
Epidemiology and etiology
Pathogenesis
Clinical Hx and PE


Systemic
Articular
Extra articular
Diff

Investigations Labs
Imaging

Management

Rheumatoid Arthritis

Definition



Systemic

Predominance in synovial joints

Synovial mb → synovitis proliferative
Art cartilage → destruction
Bone → erosion
Tendon → stretching
Ligaments → stretching

→ deformities → disability

Epidemiology/Etiology

1% of adults

♀ > ♂ 3:1

♀: ↑ incidence → 50 y → plateau

♂: rare before 40 y → ↑

New onset ♀ and ♂ at 70-90 not uncommon

HLA DR 4 +++++ (Shared epitope) in hyper variable region

Concordance rate in monozygote twins: **15%**

Strong genetic component

Other factors must be implicated

Smoking associated with a subset of patients with anti CCP ab.

1/3 RA patients - no smoking hx - other factors implicated

1. 1% of adults
2. Twins concordance
3. 3:1 sex ratio ♀: ♂
4. rare before 40 y in ♂ then ↑
5. ↑ → 50 y in ♀ then —

Pathogenesis

Ab anti-CCP → specific
RF → non specific

Complex interaction $\left\{ \begin{array}{l} \text{APC: } \text{M}\phi, \text{ DC} \\ \text{T cells} \\ \text{B cells} \end{array} \right\} \rightarrow \text{auto Ab}$
Lymph. gg

RA joint: cells above
synovocytes
Neutrophils

Pro inflammatory cytokines

$\text{TNF}\alpha, \text{IL } 1, \text{IL } 6$

$\text{IL } 23 \text{ (by Th } 17) \rightarrow \text{erosion}$

Clinical

Onset - symmetrical polyarthritis primarily MCP, PIP and MTP with morning stiffness

Systemic

Fatigue
Weight loss
Anemia
Systemic inflam.
↓
blood vessels
damage
↓
atherosclerosis

Articular

Order of joint involvement:
Early: MCP, PIP, MTP
Interm.: wrist, ankle, elbow, knee
Late: Shoulders, hips, C1-C2

Starts in small art of hands
and feet

effusion → soft tissue swelling
→ stretching of ligaments → deformities

C1-C2 subluxation → to take
significant flexion → X Ray
surgery under anesthesia

Extra art

Skin: s/c nodules also in lung
heart
pyoderma gangrenosum

Cardiopulmonary

* CAD and atherosclerosis
* Pleural/pericardial effusions
Constrictive pericarditis → rare
* Interstitial lung disease
bronchiectasis, nodules

Sjogren Sd

Eyes: scleritis and episcleritis

Hematologic

Anemia → chronic disease
Thrombocytosis
Felty sd: Leucopenia
Large Granular Lymphocyte

Vasculitis

Systemic = mimic polyarteritis nodosa
Localized: s/c nodules and digital infarcts
Bones: osteoporosis → f#

Diff Dx

Viral arboviral
OA

Other forms of inflammatory arthritis: lupus, psoriatic, crystalline

Investigations

Labs: Anemia Thrombocytosis

↑ CRP and ESR

Ab: RF
anti-CCP

ANA 1/3 → severe disease

Imaging

Plain X Ray of hands and feet
periart osteopenia
marginal erosions


Radioc. of C spine → C1-C2 subluxation

Chest X Ray and CT → pulmonary involvement

Histology: Synovial biopsy

Synovial layer hypertrophy - r/folds
hyperplasia, angiogenesis and infiltration
of predominantly CD4+ T cells, B and macrophages

644



NSAID

NSAID
(Co)
↓
Ibuprofen
Mefenamic acid
NEVER
monotherapy

+ DNARD
(everyone)

Methotrexate

- Leflunomide
- Hydroxychloroquine
- Sulfasalazine

+ Biologic ..
(severe)

- TNF α inhib
 - infliximab
 - rituximab
 - etanercept

↑ Before

- Vaccination
- TB
- Fungi

stewards

Planes

↓
Prednisone (short term)

Combine DNARD, before going to Biologics

CCP $\rightarrow$ more expensive $\rightarrow$ more specific
RF $\rightarrow$ cheaper $\rightarrow$ more sensitive

DMARDs

MTX $\rightarrow$ 1st line

Leflunomide $\rightarrow$ 2nd line

Hydroxy $\rightarrow$ if we can't use $\uparrow$ Pregnancy
non erosive disease

Sulfasalazine $\rightarrow$ additive

Morning stiffness + C1-C2 $\rightarrow$ RA
xRay: Pre-Op

Felty syndrome: RA + SPMG + Neutropenia

MTX 1st

Leflunomide 2nd

Hydroxy + 3rd

Sulfasalazine + 4th $\oplus \rightarrow$ add

Pregnant } $\rightarrow$ Start hydroxychloroquine
Non erosive }